通过生物信息学分析鉴定CYB561与浸润性乳腺癌不良预后相关

通过生物信息学研究细胞色素b561(Cytochromes b561,CYB561)与浸润性乳腺癌(Breast invasive carcinoma,BRCA)不良预后的相关性.CYB561氨基酸序列高度保守,在人体组织中广泛表达,可能预示着广泛的细胞功能.CYB561在多种癌症中的失调,提示其可能参与人类癌症发生发...

Analysis of poor prognosis of breast invasive carcinoma associatedwith CYB561 through bioinformatics

The purpose of this study is to investigate the correlation between cytochromes b561 (CYB561) and poor prognosis of breast invasive cancer (BRCA) through bioinformatics. The amino acid sequences of CYB561 are highly conserved and it is widely expressed in human tissues, which may imply a wide range of cell functions. The imbalance of CYB561 in a variety of cancers suggests that it may be involved in the development of human cancer. According to Oncomine and TIMER databases, CYB561 expression is differentially expressed in various cancers, including BRCA, compared with adjacent normal tissues. A subgroup analysis of clinicopathological characteristics using the UALCAN database showed that CYB561 expression was upregulated in BRCA patients of different races and subtypes compared with normal controls. Analysis of the cBioPortal database showed that there were genetic variations in the CYB561 genome, including copy number amplification, fusion, and missense mutations with unknown significance. By analyzing the differentially expressed genes in CYB561 and BRCA through the LinkedOmics and WebGestalt databases for enrichment analysis, the biological function of CYB561 in BRCA could be inferred. Analysis of the prognostic values of CYB561 by PrognoScan and GEPIA database showed that high CYB561 expression was significantly related to the poor prognosis of BRCA. Immune cells were involved in the prognosis of BRCA. The relationship between immune cells and the expression of CYB561 was studies. It was found that immune infiltrating B cells affected the prognosis, and it might be related to CYB561 in BRCA. Currently, there are few studies on CYB561, and there is no report of CYB561 on BRCA. We conducted data mining through different open databases, studied CYB561 expression and mutation data in BRCA patients, analyzed the biological processes that it may participate in, and found for the first time that CYB561 is dysregulated in BRCA and is associated with poor prognosis. This paper provides evidence for CYB561 as a potential prognostic biomarker for BRCA, reveals the importance of CYB561, lays a foundation for further study of the role of CYB561 in BRCA, and offers a valuable clue for subsequent clinical studies.